Recombinant Human CEACAM-5/CD66e Protein, CF
Recombinant Human CEACAM-5/CD66e Protein, CF Summary
Product Specifications
Lys35-Ala685, with a C-terminal 6-His tag
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
4128-CM
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
Recombinant Human CEACAM-5/CD66e (Catalog # 4128-CM) has a molecular weight (MW) of 203.6 kDa as analyzed by SEC-MALS, suggesting that this protein is a homodimer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).
Reconstitution Calculator
Background: CEACAM-5/CD66e
CEACAM-5, also known as CEA and CD66e, belongs to the large family of CEACAM and pregnancy specific glycoproteins. CEACAM molecules are either transmembrane or GPI-linked, and are differentially expressed between species (1, 2). Orthologs of human CEACAM-5 have not been described in other species. CEACAM-5, which is expressed primarily by epithelial cells, consists of an N-terminal Ig-like V-set domain followed by six Ig-like C2-set domains and a GPI anchor
(2-4). CEACAM-5 is synthesized as a 180 kDa, variably glycosylated molecule of which approximately 60% is carbohydrate (5). CEACAM-5 functions as a
calcium-independent adhesion molecule through homophilic and heterophilic interactions with CEACAM-1 (6-8). CEACAM-5 is restricted to the apical face of intestinal epithelial cells in the adult but is more diffuse during embryonic development and in tumors (7). This is consistent with a role in the development and maintenance of epithelial architecture. CEACAM-5 is up-regulated in a wide variety of human tumors and is a commonly used cancer marker (9). It promotes tumor cell migration, invasion, adhesion, and metastasis (10). It also contributes to tumor formation by maintaining cellular proliferation in the presence of differentiation stimuli, and by blocking apoptosis following loss of ECM anchorage (anoikis) (11, 12). The GPI anchoring of CEACAM-5 can be released by GPI-PLD, resulting in a soluble molecule that also promotes tumor metastasis (13). Cell surface expression of CEACAM-5 on tumor cells prevents the adhesion of CEACAM-1 expressing NK cells and provides protection from NK-mediated lysis (6). CEACAM-5 also binds a subset of Neisseria opacity proteins (Opa) and E. coli adhesion proteins (14-16). These interactions trigger clustering of the lipid raft-localized CEACAM-5 to sites of pathogen contact (15, 16).
- Zebhauser, R. et al. (2005) Genomics 86:566.
- Hammarstrom, S. (1999) Semin. Cancer Biol. 9:67.
- Schrewe H. et al. (1990) Mol. Cell. Biol. 10:2738.
- Hefta, S.A. et al. (1988) Proc. Natl. Acad. Sci. 85:4648.
- Garcia, M. et al. (1991) Cancer Res. 51:5679.
- Stern, N. et al. (2005) J. Immunol. 174:6692.
- Benchimol, S. et al. (1989) Cell 57:327.
- Zhou, H. et al. (1993) J. Cell Biol. 122:951.
- Goldenberg, D.M. et al. (1976) J. Natl. Cancer Inst. 57:11.
- Blumenthal, R.D. et al. (2005) Cancer Res. 65:8809.
- Screaton, R.A. et al. (1997) J. Cell Biol. 137:939.
- Ordonez, C. et al. (2000) Cancer Res. 60:3419.
- Yamamoto, Y. et al. (2005) Biochem. Biophys. Res. Commun. 333:223.
- Chen, T. et al. (1997) J. Exp. Med. 185:1557.
- Bos, M.P. et al. (1997) Infect. Immun. 65:2353.
- Berger, C.N. et al. (2004) Mol. Microbiol. 52:963.
Citation for Recombinant Human CEACAM-5/CD66e Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
-
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
Authors: M Yarchoan, CY Huang, Q Zhu, AK Ferguson, JN Durham, RA Anders, ED Thompson, NS Rozich, DL Thomas, JM Nauroth, C Rodriguez, A Osipov, A De Jesus-A, DT Le, AG Murphy, D Laheru, RC Donehower, EM Jaffee, L Zheng, NS Azad
Cancer Med, 2019-12-26;0(0):.
Species: Human
Sample Types: Serum
Applications: ELISA Capture
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human CEACAM-5/CD66e Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human CEACAM-5/CD66e Protein, CF and earn rewards!
Have you used Recombinant Human CEACAM-5/CD66e Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
